Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. (Q38262922)

1 September 2017

1 reference

title

Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. (English)

1 reference

1 September 2017

0 references

Guido Stirnimann

1

1 reference

PubMed ID

25347030

1 September 2017

language of work or name

English

0 references

publication date

27 October 2014

1 reference

Expert Opinion on Pharmacotherapy

1 September 2017

1 reference

1 September 2017

15

1 reference

1 September 2017

2609-2622

1 reference

1 September 2017

17

1 reference

Evolving epidemiology of hepatitis C virus

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Biological and clinicopathological features associated with hepatitis C virus type 5 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Molecular epidemiology of hepatitis C genotype 6a from patients with chronic hepatitis C from Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Epidemiology of viral hepatitis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

New horizons in hepatitis C antiviral therapy with direct-acting antivirals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Determinants for membrane association of the hepatitis C virus NS2 protease domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Correlation between NS5A dimerization and hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Rapid emergence of protease inhibitor resistance in hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

NS5A inhibitors in the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Antiviral therapy of hepatitis C in 2014: do we need resistance testing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Strategies to manage hepatitis C virus (HCV) disease burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972364

10.1517/14656566.2014.972364

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wdkrc4sffbbn3ceh6cqjsk73ly

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_wdkrc4sffbbn3ceh6cqjsk73ly

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wdkrc4sffbbn3ceh6cqjsk73ly

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/wdkrc4sffbbn3ceh6cqjsk73ly